期刊文献+

MGUS、原发性轻链型淀粉样变、MM及MM继发淀粉样变性患者的临床分析 被引量:2

Clinical Analysis of Patients with MGUS,Primary Light Chain Amyloidosis,Multiple Myeloma or Multiple Myeloma with Concurrent Amyloidosis
下载PDF
导出
摘要 目的:总结并比较意义未明的单克隆丙种球蛋白血症(MGUS)、原发性轻链(pAL)型淀粉样变、多发性骨髓瘤(MM)以及MM继发淀粉样变性患者的临床基线特点,尤其是细胞遗传学异常的差异。方法:回顾性分析和比较2006年2月至2019年8月于中国医学科学院血液病医院淋巴瘤诊疗中心就诊,并完善了细胞遗传学异常检测的15例MGUS、34例pAL、842例MM和23例MM继发淀粉样变性患者的临床资料。结果:细胞遗传学统计显示,4组(MGUS vs pAL vs MM vs MM继发淀粉样变性)中t(11;14)易位发生率分别为0%、33.3%、16.4%和15.8%(P=0.037);13q缺失发生率分别为20.0%、14.7%、45.8%和56.5%(P<0.001);1q21扩增发生率分别为50.0%、12.5%、47.4%和40.9%(P=0.001)。31例pAL患者累积发生0个、1个和≥2个细胞遗传学异常(包括13q缺失、17p缺失、1q21扩增和IgH易位)的比例分别为41.9%、41.9%和16.1%;MM患者对应的该比例分别为17.6%、27.3%和55.2%;MM继发淀粉样变性的这一比例与MM相似。亚组分析显示,pAL患者中t(11;14)阴性与阳性两亚组合并其他遗传学异常比例相当(包括13q缺失、17p缺失和1q21扩增);而MM+MGUS患者中t(11;14)阴性病例更易合并13q缺失,且更常同时发生多个遗传学异常。结论:pAL的临床特点,尤其细胞遗传学异常特征与MM及MM继发淀粉样变性具有明显差异。这提示,虽然pAL与MM继发淀粉样变性的起病特征相似,但是二者分属于不同疾病亚型,应仔细加以鉴别。 Objective:To summarize and compare the clinical baseline characteristics of patients with monoclonal gammopathy of undetermined significance(MGUS),primary light chain amyloidosis(pAL),multiple myeloma(MM),or MM with concurrent amyloidosis,especially the differences in cytogenetic abnormalities.Methods:The clinical data of15 cases of MGUS,34 cases of pAL,842 cases of MM and 23 cases of MM with concurrent amyloidosis were analyzed and compared retrospectively.Results:Cytogenetic statistics showed that the incidence of t(11:14) in the four groups(MGUS vs pAL vs MM vs MM with concurrent amyloidosis) was 0%,33.3%,16.4%,and 15.8%,respectively(P=0.037);that of 13 q deletion was 20.0%,14.7%,45.8% and 56.5%,respectively(P<0.001);gain of 1 q21 was 50.0%,12.5%,47.4%and 40.9%,respectively(P=0.001).Proportion of pAL patients with 0,1 and ≥2 cytogenetic abnormalities(including 13 q deletion,17 p deletion,1 q21 amplification and IgH translocation) accounted for 41.9%,41.9% and 16.1%,respectively;while the proportion of the same category in MM was 17.6%,27.3%,and 55.2% respectively;this ratio of MM with concurrent amyloidosis was more similar to MM.Subgroup analysis showed that genetic abnormalities(including 13 q deletion,17 p deletion and 1 q21 amplification) were comparable within t(11:14) negative and positive groups.Compared with positive cases,t(11;14) negative patients with MM or MGUS were more likely to have 13 q deletions and multiple genetic abnormalities.Conclusion:Clinical characteristics of pAL,especially cytogenetic abnormalities,are significantly different from MM with concurrent amyloidosis.It suggests that although the onset characteristics are similar,actually the two diseases belong to different disease subtypes which should be carefully predicted and identified.
作者 毛雪涵 邓书会 隋伟薇 傅明伟 刘佳慧 樊慧守 邹德慧 赵耀中 邱录贵 安刚 MAO Xue-Han;DENG Shu-Hui;SUI Wei-Wei;FU Ming-Wei;LIU Jia-Hui;FAN Hui-Shou;ZOU De-Hui;ZHAO Yao-Zhong;QIU Lu-Gui;AN Gang(State Key Laboratory of Experimental Hematology,National Clinical Research Center for Blood Diseases,Institute of Hematology&Blood Diseases Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Tianjin 300020,China)
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2021年第3期812-818,共7页 Journal of Experimental Hematology
基金 国家自然科学基金项目(81920108006,81630007,81400174) 中国医学科学院中央级公益性科研院所基本科研业务费(2018RC320011)。
关键词 原发性轻链型淀粉样变 意义未明的单克隆丙种球蛋白血症 多发性骨髓瘤继发淀粉样变性 多发性骨髓瘤 细胞遗传学异常 primary light chain amyloidosis monoclonal gammopathy of undetermined significance multiple myeloma-associated amyloidosis multiple myeloma cytogenetic aberration
  • 相关文献

参考文献5

二级参考文献85

  • 1Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med, 2003 ;349(6) :583 - 596.
  • 2Madan S, Dispenzieri A, Lacy MQ, et al. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clin Proc,2010 ;85 (3) :232 - 238.
  • 3Comenzo RL, Zhou P, Fleisher M, et al. Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood,2006 ; 107 (9) :3489 - 3491.
  • 4Vrana JA, Gamez JD, Madden B J, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood, 2009;114 (24) :4957 - 4959.
  • 5Michael M, Kastritis E, Delimpassi S, et al. Clinical charac- teristics and outcome of primary systemic light-chain amyloidosis in Greece. Clin Lymphoma Myeloma Leuk, 2010 ; 10 ( 1 ) :56 - 61.
  • 6Cohen AD, Comenzo RL. Systemic light chain amyloidosis: advances in diagnosis, prognosis, and therapy. Hematology Am Soc Hematol Ednc Program, 2010 ;2010:287 - 294.
  • 7Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol, 2011 ;29(14) :1924 -1933.
  • 8Dietrich S, Schonland SO, Benner A, et al. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood, 2010; 116(4) :522 -528.
  • 9Chee CE, Lacy MQ, Dogan A, et al. Pitfalls in the diagnosis of primary amyloidosis. Clin Lymph Myel Leuk,2010 ; 10 ( 3 ) : 177 - 180.
  • 10Deshmukh M, Elderfield K, RahemtuUa A, et al. Immuno- phenotype of neoplastic plasma cells in AL amyloidosis. J Clin Pathol, 2009; 62(8): 724-730.

共引文献425

同被引文献18

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部